Ranibizumab is a Medicine belongs to Miscellaneous group whose information about Brand can be referenced from   Book : Martindale    Page : 2611   Edition : 37,

  ►   Brandname : Lucentis

  ►  Strength : Injection with 10  mg/ml,

Reference of this Medicine for its Strength can be taken from   Book : Basic & Clinical pharmacology    Page : 999   Edition : 12,
A Route of administration in pharmacology and toxicology is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration.

  ►  Route of administration : Intravitreal,
Reference :-   Book : Martindale    Page : 2611   Edition : 37,

Dosing of Medicine differ in Adult & Pediatrics ↓


Adult Dose

S.No Ailment   Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency   Additional Info
1 Neovascular (wet) age-related macular degeneration intravitreal injection 500 micrograms Injection Dose: Given once a month initially for 3 to 4 months.

Ref :-  Book : Martindale    Page : 2611   Edition : 37,




Pediatric Dose

S.No Ailment   Age Min   Age Max   Weight ( Kg ) Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency  Additional Info  

Ref :- Book :
►  Organ Affected CVS (Myocardial infarction)  

►  Side Effect : Intra-ocular inflammation, endophthalmitis, rhegmatogenous retinal detachment, retinal tear, iatrogenic traumatic cataract, red eye, eye pain, vitreous floaters, eyes irritation, increased lachrymation, sensation of a foreign body in the eye, headache, nausea, arthralgia, back pain, bronchitis, anaemia, stroke,
Ref :-   Book : Martindale    Page : 2610,2611   Edition : 37,

►  Drug Interaction : Drug interaction of Ranibizumab is with NA

  ►    Mechanism of Drug Drug Interaction :  ,
Ref :-   Book :    Page :    Edition : ,


►  Contraindication : Patients with active or suspected ocular or periocular infections, or active severe intraocular inflammation,
Ref :-   Book : Martindale    Page : 2611   Edition : 37,
  ►  Mechanism of Action :   Ranibizumab is a recombinant humanised monoclonal antibody that binds to vascular endothelial growth factor (VEGF), thereby inhibiting the angiogenesis that occurs during tumour growth.,
Ref :-   Book : Martindale    Page : 749,2610   Edition : 37,

Pathway of Dietry Product


​   ► Act.Comp / Nutrient / Food / Herb as follows :- NA


Dietry Substance Interactions


​   ► This Medicine interact with :- NA



ContraIndication Dietry Substance


​   ► This Medicine contraindicate with :- NA

►   Route of Elimination :   NA


►    Plasma Half-life :
  Min value :-   NA    Max value :-   NA


►    Peak Plasma Concentration :   Min value :-   NA    Max value :-   NA